The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies

Journal of Pharmacy and Pharmacology

Volumn 50, Issue 4, 1998, Pages 387-394

  Denny, William A ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANILINE MUSTARD DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BETA GLUCURONIDASE; BETA LACTAMASE; CARBOXYPEPTIDASE; CARZELESIN; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; CYTOTOXIN; DEACETYLVINBLASTINE; DUOCARMYCIN A; ENZYME; EPIRUBICIN; FLUCYTOSINE; GANCICLOVIR; MONOCLONAL ANTIBODY; PRODRUG; SN 23862; THYMIDINE KINASE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CELL KILLING; CONFERENCE PAPER; DRUG ACTIVATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DIFFUSION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EXTRACELLULAR FLUID; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HYPOXIA; PH; TUMOR CELL;

EID: 0031956262     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1998.tb06878.x     Document Type: Conference Paper

References (50)

1. Abraham, R., Aman, N., von Borstel, R., Darsley, M., Kamireddy, B., Renten, J., Morris, G., Titmas, R. (1994) Conjugates of COL-1 monoclonal antibody and beta-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug beta-D-galactosyl-5-fluorouridine. Cell Biophys. 24/25: 127-133
2. Anlezark, G. M., Melton, R. G., Sherwood, R. F., Coles, B., Friedlos, F., Knox, R. J. (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 44: 2289-2295
3. Anlezark, G. M., Melton, R. G., Sherwood, R. F., Wilson, W. R., Denny, W. A., Palmer, B. D., Knox, R. J., Friedlos, F., Williams, A. (1995) Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol. 50: 609-618
4. Atwell, G. J., Wilson, W. R., Denny, W. A. (1997) Synthesis and cytotoxicity of amino analogues of the potent DNA alkylating agent seco-CBI-TMI. Bioorg. Med. Chem. Lett. 7: 1493-1496
5. Bagshawe, K. D., Sharma, S. K., Springer, C. J., Rogers, G. T. (1994) Antibody-directed enzyme-prodrug therapy (ADEPT): a review of some theoretical, experimental and clinical aspects. Ann. Oncol. 5: 879-891
6. Blakey, D. C., Davies, D. H., Dowell, R. I., East, S. J., Burke, P. J., Sharma, S. K., Springer, C. J., Mauger, A. B., Melton, R. G. (1995) Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Br. J. Cancer 72: 1083-1088
7. Boger, D. L., Ishizaki, T., Zarrinmayeh, H., Kitos, P. A., Suntornwat, O. (1990) Synthesis and preliminary evaluation of agents incorporating the pharmacophore of the duocarmycin/pyrindamycin alkylation subunit: identification of the CC-1065/duocarmycin common pharmacophore. J. Org. Chem. 55: 4499-4502
8. Boger, D. L., Johnson, D. S. (1996) CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies. Angew. Chem. Int. Ed. Engl. 35: 1438-1474
9. Boland, M. P., Knox, R. J., Roberts, J. J. (1991) The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cells lines to CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem. Pharmacol. 41: 867-875
10. Bridgewater, J. A., Knox, R. J., Pitts, J. D., Collins, M. K., Springer, C. J. (1997) The bystander effect of the nitroreductase CB 1954 enzyme prodrug system is due to a cell-permeable metabolite. Human Gene Ther. 8: 709-717
11. Cobb, L. M., Connors, T. A., Elson, L. A., Khan, A. H., Mitchley, B. V. C., Ross, W. J. C., Whisson, M. E. (1969) 2,4-Dinitro-5-ethyleneiminobenzamide (CB1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem. Pharmacol. 8: 1519-1527
12. Coleman, C. N. (1988). Hypoxia in tumors: a paradigm for the approach to biochemical and physiological heterogeneity. J. Natl Cancer Inst. 80: 310-317
13. Cowan, D. S. M., Hicks, K. O., Wilson, W. R. (1996) Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br. J. Cancer 74 (Suppl. XXVII): 28-31
14. Culver, K. W. (1996) Gene therapy for malignant neoplasms of the CNS (Review). Bone Marrow Transpl. 18 (Suppl. 3): S6-S9
15. Denny, W. A. (1996) The design of selectively-activated prodrugs for cancer chemotherapy. Curr. Pharm. Design 2: 281-294
16. Denny, W. A., Wilson, W. R. (1993) Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Met. Rev. 12: 135-151
17. Denny, W. A., Wilson, W. R., Hay, M. P. (1996) Recent developments in the design of bioreductive drugs. Br. J. Cancer 74 (Suppl. XXVII): 32-38
18. 1 complex. J. Am. Chem. Soc. 112: 9669-9670
19. Dirix, L. Y., Tonnesen, F., Cassidy, J., Epelbaum, R., ten Bokkel Huinink, W. W., Pavlidis, N., Sorio, R., Gamucci, T., Wolff, I., Te Velde, A., Lan, J., Verweij, J. (1996) EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Euro. J. Cancer 32A: 2019-2022
20. Fan, J.-Y., Tercel, M., Tan, L. K., Boyd, M., Denny, W. A. (1998) Reaction of 6-amino analogues of the duocarmycin series with DNA; isolation and identification of the major adduct. Chem. Res. Tox., in press
21. Fitzsimmons, S. A., Workman, P., Grever, M., Paull, K., Camalier, R., Lewis, A. D. (1996) Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J. Natl Cancer Inst. 88: 259-269
22. Friedlos, F., Denny, W. A., Palmer, B. D., Springer, C. J. (1997) Structure-activity relationships for activation of dinitrophenylcarboxamide mustards by E. coli nitroreductase in GDEPT (gene-directed enzyme prodrug therapy). J. Med. Chem. 40: 1270-1275
23. Green, N. K., Youngs, D. J., Neoptolemos, J. P., Friedlos, F., Knox, R. J., Springer, C. J., Anlezark, G. M., Michael, N. P., Melton, R. G., Ford, M. J., Young, L. S., Kerr, D. J., Searle, P. F. (1997) Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 4: 229-238
24. Haisma, H. J., Boven, E., van Muijen, M., de Jong, J., van der Vijgh, W. J., Pinedo, H. M. (1992) A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for the specific treatment of cancer. Br. J. Cancer 66: 474-478
25. Hay, M. P., Denny, W. A. (1996) Antibody-directed enzyme-prodrug therapy (ADEPT). Drugs Future 21: 917-931
26. Hay, M. P., Wilson, W. R., Denny, W. A. (1995) A novel enediyne prodrug for antibody-directed enzyme prodrug therapy (ADEPT) using E. coli B nitroreductase. Bioorg. Med. Chem. Lett. 5: 2829-2834
27. Hicks, K. O., Ohms, S. J., van Zilj, P., Denny, W. A., Hunter, P. J., Wilson, W. R. (1997) An experimental and mathematical model for the extravascular treatment of a DNA intercalator in tumours. Br. J. Cancer. 76: 894-903
28. Holder, J. W., Elmore, E., Barrett, J. C. (1993) Gap junction function and cancer. Cancer Res. 53: 3475-3485
29. Ishii-Morita, H., Agbaria, R., Mullen, C. A., Hirano, H., Koeplin, D. A., Ram, Z., Oldfield, E. H., Johns, D. G., Blaese, R. M. (1997) Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 4: 244-251
30. Knox, R. J., Friedlos, F., Marchbank, T., Roberts, J. J. (1991) Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand cross-linking species. Biochem. Pharmacol. 42: 1691-1697
31. Knox, R. J., Friedlos, F., Jarman, M., Davies, L. C., Goddard, P., Anlezark, G. M., Melton, R. G., Sherwood, R. F. (1995) Virtual cofactors for an Escherichia coli nitroreductase enzyme-relevance to reductively activated prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 49: 1641-1647
32. Li, L. H., DeKoning, T. F., Kelly, R. C., Krueger, W. C., McGovern, J. P., Padbury, G. E., Petzold, G. L., Wallace, T. L., Ouding, R. J., Prairie, M. D., Gebhard, I. (1992) Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylindole analogue. Cancer Res. 52: 4904-4913
33. Li, Z., Shanmugam, N., Katayose, D., Huber, B., Srivastava, S., Cowan, K., Seth, P. (1997) Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther. 4: 113-117
34. Mauger, A. B., Burke, P. J., Somani, H. H., Friedlos, F., Knox, R. J. (1994) Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. 37: 3452-3458
35. Meyer, M. L., Jungheim, L. N., Mikolajczyk, S. D., Shepherd, T. A., Starling, J. J., Ahlem, C. N. (1992) Preparation and characterization of a beta-lactamase-Fab′ conjugate for the site-specific activation of oncolytic agents. Bioconjug. Chem. 3: 42-48
36. Meyer, M. L., Jungheim, L. N., Law, K. L., Mikolajczyk, S. D., Shepherd, T. A., Mackensen, D. G., Briggs, S. L., Starling, J. J. (1993) Site-specific prodrug activation by antibody-β-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res. 53: 3956-3963
37. Nicolaou, K. C., Dai, W.-M., Tsay, S.-C., Estevez, V. A., Wrasidlo, W. (1992) Designed enediynes: a new class of DNA-cleaving molecules with potent and selective anticancer activity. Science 256: 1172-1178
38. Nicolaou, K. C., Smith, A. L., Yue, E. W. (1993) Chemistry and biology of natural and designed enediynes. Proc. Natl Acad. Sci. USA 90: 5881-5888
39. Pavlidis, N., Hanauske, A. R., Gamucci, T., Smyth, J., Lehnert, M., te Velde, A., Lan, J., Verweij, J. (1996) A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). Ann. Oncol. 7: 529-531
40. Richards, C. A., Austin, E. A., Huber, B. E. (1995) Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Human Gene Ther. 6: 881-893
41. Siim, B. G., Denny, W. A., Wilson, W. R. (1997) Nitro reduction as an electronic switch for bioreductive drug activation. Oncol. Res. 9: 357-369
42. Springer, C. J., Dowell, R., Burke, P. J., Hadley, E., Davies, D. H., Blakey, D. C., Melton, R. J., Niculescu-Duvaz, I. (1995) Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme-prodrug therapy (ADEPT). J. Med. Chem. 38: 5051-5065
43. Tannock, I. F., Rotin, D. (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49: 4373-4384
44. Tercel, M., Denny, W. A., Wilson, W. R. (1996a) Nitrogen and sulfur analogues of the seco-CI alkylating agent: synthesis and cytotoxicity. Bioorg. Med. Chem. Lett. 6: 2735-2740
45. Tercel, M., Denny, W. A., Wilson, W. R. (1996b) A novel nitro-substituted seco-CI: application as a reductively activated ADEPT prodrug. Bioorg. Med. Chem. Lett. 6: 2741-2744
46. Tietze, L. F., Newman, M., Mollers, T., Fischer, R., Glusenkamp, K.-H., Rajewsky, M., Jahde, E. (1989) Proton-mediated liberation of aldophosphamide from a non-toxic prodrug: a strategy for tumor-selective activation of cytocidal drugs. Cancer Res. 49: 4179-4184
47. Wang, S.-M., Chern, J.-W., Yeh, M.-Y., Ng, J. C., Tung, E., Roffler, S. R. (1992) Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res. 52: 4484-4491
48. Wilson, W. R. (1992) Tumour hypoxia: challenges for cancer chemotherapy. In: Waring, M. J., Ponder, B. A. J. (eds) Cancer Biology and Medicine. Volume 3: The Search for Anti-Cancer Drugs, Chapter 4, Kluwer, Lancaster
49. Wilson, W. R., Denny, W. A., Tercel, M. (1996) Radiation-activated cytotoxins: a new use for Roentgen's rays in cancer treatment. In: Hagen, U., Harder, D., Jung, H., Streffer, C. (eds) Proc. 10th Int. Congr. Radiat. Res. Vol. 2, pp 791-794
50. Zhang, J., Russell, S. J. (1996) Vectors for cancer gene therapy. Cancer Met. Rev. 15: 385-401